Durable Response to Brentuximab Vedotin-Based Chemotherapy in Refractory Hodgkin Lymphoma with Central Nervous System (CNS) Involvement
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F20%3A43919992" target="_blank" >RIV/00216208:11120/20:43919992 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/20:10409958 RIV/00064173:_____/20:N0000146 RIV/00064203:_____/20:10409958
Result on the web
<a href="https://doi.org/10.12659/AJCR.921657" target="_blank" >https://doi.org/10.12659/AJCR.921657</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.12659/AJCR.921657" target="_blank" >10.12659/AJCR.921657</a>
Alternative languages
Result language
angličtina
Original language name
Durable Response to Brentuximab Vedotin-Based Chemotherapy in Refractory Hodgkin Lymphoma with Central Nervous System (CNS) Involvement
Original language description
BACKGROUND CNS involvement in Hodgkin lymphoma is rare. Despite various treatment options, median overall survival is only 13 months after diagnosis of CNS involvement in relapsed/refractory HL. CASE REPORT A 29-year-old woman with classical HL (mixed cellularity) in clinical stage IIB was treated with multilineage chemotherapy and radiotherapy without achieving a sustained complete remission. Systemic and CNS progression of HL occurred at the age of 32 years and the patient received 2 cycles of brentuximab vedotin with bendamustine alternating with 2 cycles of high-dose methotrexate-based treatment and achieved partial remission. She then underwent autologous stem cell transplantation followed by brentuximab vedotin consolidation. The disease progressed and the patient died 6 months after the last dose of brentuximab vedotin. CONCLUSIONS We demonstrated a durable response to brentuximab vedotin-based chemotherapy in a patient with refractory Hodgkin lymphoma with CNS involvement. Prognosis of these patients is poor and new treatment options are needed.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
<a href="/en/project/NV16-29857A" target="_blank" >NV16-29857A: Cognitive impairment, structural and functional brain morphological sequelae of Hodgkin lymphoma treatment: Translational study.</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
American Journal of Case Reports
ISSN
1941-5923
e-ISSN
—
Volume of the periodical
21
Issue of the periodical within the volume
March
Country of publishing house
US - UNITED STATES
Number of pages
4
Pages from-to
"Article e921657"
UT code for WoS article
000519735000001
EID of the result in the Scopus database
2-s2.0-85081950544